Skip to main content

Agomelatine use while Breastfeeding

Medically reviewed by Drugs.com. Last updated on Nov 15, 2022.

Agomelatine Levels and Effects while Breastfeeding

Summary of Use during Lactation

Agomelatine is not approved for marketing in the United States by the U.S. Food and Drug Administration (FDA), but is available in other countries. A minimal amount of information indicates that exposure and adverse effects can be avoided in breastfed infants if breastfeeding is held for 4 hours after a dose. Whether breastfeeding during the 4-hour period would affect the infant has not been studied.

Drug Levels

Maternal Levels. A woman who was taking quetiapine 200 mg daily for postpartum psychosis had agomelatine 25 mg daily added after 1 week of therapy because of depressive symptoms. A mixture of fore- and hindmilk samples were collected 10 min before and 30, 60, 90, 120, and 240 minutes after each dose for the first 3 days of agomelatine therapy. Peak agomelatine milk levels of 0.78 to 2 mcg/L occurred at 60 to 120 minutes after the dose. On all 3 days, the milk concentration was undetectable (<0.1 mcg/L) at 240 minutes after the dose.[1]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

A woman with severe postpartum depression was given agomelatine 25 mg daily at bedtime. She breastfed her infant for 12 weeks, taking the dose after her last breastfeeding of the day and then pumping her milk in the morning before resuming breastfeeding. Her use of formula, if any, was not mentioned. She breastfed normally during the day. Her infant developed normally and had no abnormal laboratory values or adverse effects during the 12-week period.[2]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Nortriptyline, Paroxetine, Sertraline

References

1.
Schmidt FM, Lichtblau N, Uribe MM, et al. Agomelatine in breast milk. Int J Neuropsychopharmacol. 2013;16:497–9. [PubMed: 22781637]
2.
Xiao L. Agomelatine for postpartum depression and breastfeeding. Ther Adv Psychopharmacol. 2021;11 [PMC free article: PMC8182171] [PubMed: 34158917] [CrossRef]

Substance Identification

Substance Name

Agomelatine

CAS Registry Number

138112-76-2

Drug Class

Breast Feeding

Lactation

Antidepressants

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.